Abstract 1069
Background
Alectinib is a CNS penetrant and highly selective ALK inhibitor. The Japanese Risk Management Plan based on the phase I/II studies highlighted interstitial lung disease (ILD), liver function disorder, decreased neutrophil cell and white blood cell counts as identified risk in Japanese patients (pts). To investigate the safety and effectiveness of alectinib, including adverse drug reactions (ADR) of particular concern in the real world setting, a large scale surveillance funded by Chugai Pharmaceuticals has been implemented. This study is registered with the UMIN, number UMIN000014989.
Methods
From Sep 2014 to June 2015 all pts with ALK-positive recurrent/advanced NSCLC treated with alectinib, were enrolled in the study. The observation period was 18 months, ADR were collected. Overall survival (OS) was also assessed.
Results
By Jun 2015, a total of 1251 pts were registered. We analysed 1221 pts as the safety population. Baseline characteristics included: female (54% of population), median age (62 years), ECOG PS 3-4 (n = 89) (7%), pts who received first line (18%), second line (32%) or third line or more (50%) treatments, pts who received crizotinib (63%), brain metastases (41%). The overall incidence of ADRs was 53.6% (mostly grade 1/2), the most common were laboratory tests abnormality (27.7%). ILD events were reported in 47 pts (3.8% of population), including grade 3 events in 8 pts and grade 4 events in 1 pt, in which the rate of recovery or improvement was 92%. Events of liver function disorder were reported in 242 pts (19.8%), including grade 3 events in 24 pts, and events of neutrophil cell and white blood cell decrease were reported in 93 pts (7.6%), including grade 3 events in 12 pts and grade 4 events in 2 pts, in which the rates of recovery or improvement were 83% and 93%, respectively. Median OS was not reached. Overall survival rate at 12 months and 18 months were 82.4% and 76.2%, respectively.
Conclusions
These final data from this study in Japanese ALK-positive NSCLC pts provide an acceptable safety and effectiveness profile in the real-world setting. Alectinib was primarily one of the effective therapies for the treatment of ALK-positive NSCLC.
Clinical trial identification
Legal entity responsible for the study
Chugai Pharmaceutical CO., LTD.
Funding
Chugai Pharmaceutical CO., LTD.
Editorial Acknowledgement
Disclosure
Y. Ohe: Consuting or advisory role, honoraria: Chugai Pharm Co., Ltd.; Research funding to institution: Chugai Pharm Co., Ltd. N. Yamamoto: Consuting or advisory role, speakers' bureau, honoraria: Chugai Pharm Co., Ltd. Research funding to instution: Chugai Pharm Co., Ltd. A. Gemma, M. Kusumoto, N. Masuda: Consuting or advisory role: Chugai Pharm CO., LTD. I. Yamada, T. Ishii: Employment: Chugai Pharm Co., Ltd.
Resources from the same session
2300 - AXL has a prognostic role in metastatic colorectal cancer (mCRC) and is a predictive biomarker of lack of efficacy of chemotherapy (CT) + cetuximab in RAS wild type (WT) patients (pts)
Presenter: Claudia Cardone
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2834 - Multimodal detection of homologous recombination repair gene mutations (HRRm) in a Phase II trial of olaparib plus abiraterone in metastatic castrate resistant prostate cancer (mCRPC)
Presenter: Thomas Carr
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3596 - Identification of a highly suppressive Treg subset associated to immunotherapy response
Presenter: Emilio Giunta
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3705 - A Novel Framework for Evaluating Biomarker Response Relationships in Immuno-oncology (IO)
Presenter: Jeffrey Evelhoch
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5332 - Comparison of OncoBEAM and NGS methods to detect plasma EGFR T790M mutations at progression of NSCLC
Presenter: Jessica Garcia
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5700 - Differential expression of PD-L1 and immune biomarkers by age: Decreased expression in pediatric/AYA patients with advanced cancer
Presenter: Omid Hamid
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
966 - Potential resistance mechanisms revealed primary resistance to crizotinib in ROS1+ non-small-cell lung cancer using next generation sequencing: A multicenter study
Presenter: Quxia Zhang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2171 - Prevalence of CLDN18.2, HER2, and PD-L1 in Gastric Cancer Samples
Presenter: Diarmuid Moran
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2318 - Epigenetic markers in circulating cell-free DNA for detection of early stage colorectal cancer
Presenter: Yanqun Liu
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3625 - Detection and clearance of RET variants in plasma cell free DNA (cfDNA) from patients (pts) treated with LOXO-292
Presenter: Benjamin Besse
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract